You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
By chopping RNA-seq reads into smaller bits, UW-Tacoma data scientists are able to cut the alignment step to one minute, but the approach has skeptics.
Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.
At the AMP 2020 annual meeting, the Chicago pediatric hospital described how to modernize variant calling, as new human genome assemblies are in the works.
Translational informatics company Paradigm4's new Reveal: SingleCell app is built on its core SciDB platform that supports fast querying of large multiomic datasets.
Researchers found complex "rigma," "pyrgo," and "tyfona" structural variant classes by applying their new algorithm to thousands of cancer genomes.
The Boston-based firm is pursuing nanopore technology as a readout for its unique information-encoding format, which could help customers store vast amounts of data.
A computational method, coupled with PCR analysis and RNA-seq, helped researchers pinpoint several drugs that could be repurposed to fight COVID-19.
In Science this week: 29 widespread antiviral gene cassettes uncovered, and more.
In a newly published paper, CHOP researchers described a method for rebuilding patient histories en masse to create gene-specific "footprints" in clinical records.
The grant will allow Weill Cornell to study genetic, social, and clinical factors that might explain why COVID-19 disproportionally affects minorities in the US.
SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.
The New York Times reports that a new viral variant of concern has been identified in New York City.
In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.
CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.